Lantern Pharma to Host Second-Quarter 2026 Results Webcast, Highlighting AI-Driven Oncology Advancements

Lantern Pharma (NASDAQ: LTRN), a clinical-stage precision oncology company that leverages artificial intelligence to accelerate drug development, announced it will host a webcast on August 14, 2026, at 9 a.m. ET to discuss its second-quarter financial and operating results. The live event, led by President and CEO Panna Sharma along with other members of the management team, will cover the period ended June 30, 2026, and will include updates on upcoming milestones, clinical trials, and developments related to the company’s RADR® platform and its recently launched Open-Medicine AI co-scientist, Zeta.ai.

The webcast will be accessible via the investor relations section of Lantern Pharma’s website, with a replay available following the event. This announcement comes at a critical juncture for the company as it seeks to expand its revenue streams beyond traditional drug development. The commercial availability of Zeta.ai as a subscription-based research platform marks a significant shift, potentially opening new markets for the company’s AI capabilities in the global biomedical and drug development community.

Lantern’s clinical pipeline remains robust, with several candidates in various stages of development. LP-184, an acylfulvene-based compound, is being evaluated for the treatment of solid tumors and is also being developed for pediatric central nervous system cancers through Starlight Therapeutics, Lantern’s wholly owned subsidiary. LP-284, a TC-NER targeting compound, is being studied in hematologic and solid tumors. Additionally, LP-300, a cisplatin/ethacraplatin analog, is currently in the HARMONIC Phase 2 trial, which is focused on never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment.

The company’s strategic initiatives, including the establishment of an AI Center of Excellence in Bengaluru, India, and its headquarters in Dallas, Texas, position it to capitalize on the growing intersection of AI and oncology. As Lantern Pharma continues to integrate artificial intelligence into every facet of its operations, the upcoming webcast will provide investors with a comprehensive view of the company’s financial health and strategic direction. The insights shared during the call will be pivotal for stakeholders assessing the company’s progress in transforming cancer therapy development.